Hence, the suppression of the IL-6/STAT3 signalling pathway by cryptolepine (Fig. 5), as well as inflammation [24], suggest that cryptolepine could be exploited as a cheaper and novel anti-cancer agent in the management of HCC and other cancers. The gene discussed is STAT3; the disease is cancer.